ADVANCED SOLID TUMORS

This study tests a new drug called LCB84, which targets a protein (TROP2) found on many cancer cells and delivers a toxic payload directly to them. It is being tested alone and together with an immunotherapy drug (anti-PD-1) in 300 people with advanced solid tumors that have not …

This early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. Th…

This study tests an experimental drug called CM518D1 in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first to find a safe dose, then to see if the drug can shrink tumors. About 434 participants will receive the drug i…

This early-stage trial tests a new drug called BGM-2121 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug might shrink tumors.

This early-phase trial tests a new drug called VVD-159642, which targets specific cancer-driving proteins. It is given alone or with other drugs (sotorasib or trametinib) to people with advanced solid tumors that have certain genetic changes. The main goals are to check safety, f…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two phases: first, to check safety and find the right dose, and second, to see if the drug shrinks tumors. Ab…

This early-stage trial tests a new oral drug called ZX-8177 in about 80 Chinese adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink …

This early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receiv…

This study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…

This early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…

This study tests a new drug called ETX-636, taken as a pill, for people with advanced solid tumors (including breast cancer) that have a specific genetic change (PIK3CA mutation). The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestra…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This early-phase trial is testing a new treatment called NK521 for people with advanced solid tumors that have spread and caused fluid buildup in the belly (malignant ascites). The treatment uses a person's own natural killer (NK) cells that have been gene-edited to better attack…

This study tests a new drug called OTP-01 in people with advanced solid tumors that have not responded to standard treatments. OTP-01 is a dual-targeting antibody designed to block two cancer pathways at once: PD-1 (which helps tumors hide from the immune system) and VEGFR2 (whic…

This study tests a combination of sirolimus (a targeted therapy) with several antibody-drug conjugates (ADCs) in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if the combo can shrink tumors. About 444 participants…

This study tests a new drug called CKD-703 in people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has a specific marker (c-Met). The drug is designed to seek out and destroy cancer cells while sparing healthy ones. The trial has three part…

This early-stage trial tests a new drug called SHR-3821 in 162 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrinkage. Participants receive the dr…

This early-stage trial is testing a new drug called BTM-3566 in 30 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and understand side effects. Participants take the drug for 7 days on and 7 days off, and res…

This early-stage trial is testing an experimental drug called AMT-253 in about 96 people with advanced melanoma or other solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and then, seeing if the drug can shrink tumor…

This early-stage trial is testing a new drug called BAT8008 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target a protein called Trop2 found on many cancer cells. The main goals are to check safety, find the best dos…

This study tests a new drug called HRS-6768 in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: the first checks safety and the best dose, and the second looks at whether the drug can slow tumor growth. About 84 participa…

This study tests an experimental oral drug called JAB-23E73 in adults with advanced solid tumors that have a KRAS alteration. The goal is to find a safe dose and see if it can shrink tumors. About 294 participants will take the pill, and researchers will monitor side effects and …

The TAPUR study is testing whether giving targeted cancer drugs based on a tumor's specific genetic changes can help people with advanced solid tumors, lymphoma, or multiple myeloma. About 4200 participants whose cancer has stopped responding to standard treatments will receive o…

This early-phase trial is testing an experimental drug called SKB445 in 126 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and get an early look at whether the drug can shrink tumors. Part…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This early-stage trial tests a new drug called SKB518 in 150 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants receive the drug every …

This study tests a new biologic drug called ASKG915, given alone or with standard chemotherapy, in about 594 people with advanced solid tumors that no longer respond to available treatments. The main goals are to check the drug's safety and how the body processes it. The trial is…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-stage study tests a new drug called navlimetostat in 32 Japanese and Chinese patients with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goal is to check the drug's safety and how the body processes it. Participants must have tumor…

This trial tests an experimental drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, and colorectal cancers. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants receive the drug every 3 weeks and are monitor…

This study tests a new drug called BMS-986482, given alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. About 413 adults will take part to see if the drug is safe and shrinks tumors. The goal is to find better opti…

This study tests an experimental drug called GFH375 in people with advanced solid tumors that have a specific genetic change (KRAS G12D). The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 407 adults aged 18 to 75 with advanced cancers like lung or pa…

This study tests a modified herpesvirus (T3011) combined with standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink tumors. About 68 parti…

This study tests a new drug called SHR-1826 combined with other cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 876 ad…

This study tests a new drug called HRS-4642 combined with other cancer treatments in people with advanced solid tumors that have a specific genetic change (KRAS G12D mutation). The goal is to find the safest dose and see if the combination can shrink tumors. About 118 adults aged…

This early-phase study tests a new drug called FS-8002 in 66 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps control the cancer. Participants will receive FS-…

This study tests a new drug called SKB105 in 256 adults with advanced solid tumors that have not responded to standard treatments. SKB105 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial will first find the safest dose, then check…

This early-stage trial tests NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that no longer respond to standard treatments. Participants first receive two chemotherapy drugs to prepare their immune system, then get…

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The trial involves 360 participants and aims to check safety and how well the drug works. It is an early-stage study, so results a…

This early-phase trial tests a new drug called 177Lu-RAD202, which is a radioactive antibody designed to seek out and deliver radiation directly to HER2-positive cancer cells. The study involves 30 adults with advanced solid tumors that have not responded to standard treatments. …

This early-stage trial is testing a new oral drug called PAS-004 in 48 people with advanced solid tumors that have RAS, NF1, or RAF mutations. The main goals are to find safe doses and understand side effects. Participants take PAS-004 daily for up to 2 years, with regular health…

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This early-phase trial is testing a new biologic drug called SBO-154 in people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink…

This early-phase study tests a new oral drug, TYRA-430, in about 100 adults with advanced liver cancer or other solid tumors that have specific FGF/FGFR gene changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for early signs…

This study tests an experimental drug called MRG006A in 343 adults with advanced solid tumors that have spread or cannot be removed. The goal is to find the safest dose and see if the drug can shrink tumors. Participants receive the drug through an IV, and researchers monitor sid…

This study tests whether giving cancer drugs that target specific genetic changes in a person's tumor can help shrink or control their cancer. It includes 720 adults with advanced solid tumors, lymphoma, or multiple myeloma who have no standard treatment options. Participants rec…

This early-stage trial tests a new drug called GenSci143 in 180 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can shrink tumors. Participants receive GenSci143 by injectio…

This early-stage trial is testing a new drug called GS-2121, taken as a tablet, alone or with an intravenous drug called zimberelimab, in 154 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, …

This study tests a new medicine, SNV4818, in about 320 adults with advanced solid tumors that have a specific genetic change (PIK3CA mutation) and have not responded to other treatments. The main goals are to check safety and find the best dose, either alone or with other cancer …

This early-phase study tests a new cell therapy called GK01 in 10 people with advanced lung or esophageal cancer that no longer responds to standard treatments. The main goal is to check safety and how the body handles the therapy. Researchers will also look for early signs of tu…

This early-phase study tests an experimental tablet, JMKX005425, in people with advanced solid tumors that have high microsatellite instability or mismatch repair deficiency. The main goals are to check the drug's safety and find the right dose. About 102 participants will take t…

This early-phase study tests whether a new type of immune cell therapy, called Meta10-TIL, is safe for people with advanced solid tumors that have not responded to standard treatments. The therapy involves taking immune cells from the patient's own tumor, modifying them to work b…

This early-phase study tests a new drug called AK146D1 in 200 people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer targets (Trop2 and Nectin4) and deliver a toxic payload directly to tumor cells. The m…

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS mutations. The main goal is to check the drug's safety and side effects, not to cure the cancer. Participants must …

This early-phase study tests an experimental drug called MK-0472, given alone or with other cancer drugs (pembrolizumab or MK-1084), in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see how well the drug works. Ab…

This study tests a new drug called DT-7012, alone or with another cancer drug, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and can shrink tumors. About 125 adults will take part in this early-phase trial.

This study tests a new drug called XNW28012 in people with advanced solid tumors (like pancreatic, ovarian, or cervical cancer) who have tried other treatments without success. The goal is to find a safe dose and see if the drug can shrink tumors. About 350 people will take part …

This study tests a new treatment called EB-NK-301 for adults with advanced solid tumors that have stopped responding to standard therapies. The treatment uses specially engineered immune cells (CAR NK cells) to target a protein called TROP2 found on many cancer cells. The main go…

This study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug shrinks tumors. About 160 adults with certain cancer types…

This early-stage study tests a new drug called HWS116 in about 56 adults with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check the drug's safety and see if it can shrink tumors.…

This study tests an experimental drug called marlotamig (REGN7075) alone and with cemiplimab (with or without chemotherapy) in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 933 parti…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This early-stage study tests a new drug, ACR246, in about 77 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body a…

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers. The goal is to check the drug's safety and see if it can shrink or control tumors. About 156 participants will receive the drug intravenousl…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage study tests a new drug called HRS-3802 in 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the drug …

This early-phase study tests a personalized cell therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow them in a lab, and infuse them back after a short chemotherapy preparation. Th…

This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…

This early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …

This early-phase study tests a new drug called AMT-676 in about 24 adults with advanced solid tumors that have not responded to other treatments. The drug is designed to target and attack cancer cells. The main goals are to find the safest dose and check for side effects.

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This study tests a new drug called SHR-A1904 in people with advanced solid tumors, specifically stomach or pancreatic cancer that has not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 83 adults will take part in th…

This early-phase study is testing a new drug called MK-1084, alone or with other treatments, in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The main goals are to check the drug's safety, how the body processes it, and whether it can shrink t…

This early-phase study tests a new drug, ASP1002, in adults with advanced solid tumors that have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find the best dose, and see how well people tolerate it. Participants receive the drug throug…

This early-phase study tests an experimental drug called HDM2006 in about 48 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will re…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This early-phase study tests a new drug called VVD-130037 in people with advanced solid tumors that have stopped responding to standard treatments. The drug aims to activate a protein (KEAP1) to fight cancer. Researchers will check safety, side effects, and whether the drug works…

This early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…

This study tests a new drug called MK-3120 in about 270 adults with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to check the drug's safety and whether people can tolerate it. Participants must have already tried all available standard…

This early-phase study tests the safety and best dose of SKB315, a drug designed to attack cancer cells with a specific protein called Claudin18.2. About 246 adults with advanced solid tumors that haven't responded to standard treatments will receive the drug. The goal is to see …

This early-stage study tests a new drug called HS-20122 in about 1,050 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. Participants will receive the drug through an IV and be cl…

This early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (lung, bile duct, pancreas, or colorectal cancer) that have not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or stop…

This early-stage study tests a new tablet called GEN-725 in 48 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must be b…

This early-phase study tests a new drug called INCA33890 in about 408 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their g…

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This study tests an experimental mRNA treatment, mRNA-4359, in people with advanced solid tumors that have not responded to standard therapies. The treatment is given alone or with other immune-boosting drugs. The main goals are to check safety and find the best dose. About 361 a…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This early-stage study tests a new drug, SIM0505, in about 414 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have tried at le…

This early-stage study tests a new drug called Hemay181 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goal is to see if the drug can shrink tumors and to check for side effects. Participants will recei…

This early-phase trial tests a new drug called TEV-56278, alone or with pembrolizumab, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 240 p…

This study tests a new drug called YL202 combined with other anti-cancer treatments in people with advanced solid tumors, including breast and lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 414 adults aged 18-75 who have already tried stan…

This study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety and how well it shrinks tumors. About 110 adults who have already tried standard t…

This early-phase study tests a new drug called ALTA3263 in adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The main goal is to check the drug's safety and find the right dose. About 448 pa…

This early-stage study tests a new drug called GenSci140 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 170 adults in China will take part,…

This early-stage study tests a new drug called FID-022 in 24 people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. This is not a cure, but a first step to see if the drug can be used to c…

This study tests a new drug called SPR1020 in adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells with specific genetic changes (BRCA or HRR mutations) and may also reach brain tumors. The goal is to find a…

This early-phase trial tests whether combining an experimental drug (AT1019), targeted radiation (SBRT), and an immunotherapy (PD-1 inhibitor) is safe for people with advanced solid tumors. About 12 participants will receive the combination and be monitored for side effects and t…

This study tests a new drug, YL205, in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if it can shrink tumors. About 252 adults in China will take part in this early-phase trial.

This early-stage trial tests the safety and effectiveness of a new antibody drug called GEN1079 in 121 people with certain advanced solid tumors. The study has three parts: first finding a safe dose, then refining it, and finally checking how well it works. All participants recei…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-stage trial tests a new drug called metarrestin in people with solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. Adults with certain cancers and children aged 12-17 with solid tumors may jo…

This study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…

This early-stage study tests a new drug, HW071021, in 76 adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have spread or come back. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. Participa…

This early-stage study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 adults will take part, and the …

This study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.

This study tests an experimental capsule called WJB001 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 210 participants will be enrolled across three phases: dose fin…

This early-phase study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and to check for side effects. About …

This study tests an experimental drug called DB-1311/BNT324 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 862 adults will take pa…

This study is for people with advanced solid tumors who have a specific gene change (KRAS G12C) and are already doing well on sotorasib (with or without panitumumab) from a previous Amgen trial. It allows them to keep receiving the treatment while doctors monitor safety and side …

This early-stage study tests a new drug called SIGX1094R in about 102 adults with advanced solid tumors who have no standard treatment left. The main goals are to check the drug's safety, find the right dose, and see how it affects tumors. Researchers will also look at how food c…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This early-stage study tests a new drug called SIBP-A19 in 156 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the drug moves through the body. This is not a cure; it aims to con…

This early-stage study tests a new drug called HDM2024 in 63 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check if the drug is safe and to see if it can shrink tumors. Participants receive the drug once every three weeks,…

This study tests a new drug called GW5282 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 203 adults will take part in this early-phase trial.

This early-phase trial tests a new treatment called Meta10-TIL for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in the lab to better fight cancer. The main goal is to check saf…

This study tests an experimental pill called WJ22096 in about 20 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants take the pill by m…

This early-stage study tests a new drug called CKD-512, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 60 participa…

This study tests a new drug called CS2009, a tri-specific antibody that targets three proteins (PD-1, VEGFA, and CTLA-4) to fight advanced solid tumors. The trial has two phases: first, finding the safest dose, then expanding to see how well it shrinks tumors. About 660 adults wi…

This study tests an experimental drug called VIB305 in people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. The trial has two parts: first, finding the safest dose, and then testing that dose in more patients to see if it shri…

This early study tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a modified virus (hV01) injected directly into tumors to help the immune system fight cancer, along with an immunotherapy dru…

This study tests a new drug called RMC-5127, alone or with other medicines, in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific KRAS G12V mutation. The goal is to see if the drug is safe and can shrink tumors. About 574 particip…

This early-stage study tests a new drug called GenSci139 in about 280 people with advanced solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is currently recruiting participants.

This early-stage study tests a new drug, OKI-219, designed to attack cancer cells with a specific mutation (PI3KαH1047R). About 200 adults with advanced solid tumors or breast cancer will receive the drug alone or with other treatments. The goal is to find safe doses and see if t…

This study tests an experimental drug called SPH4336, given alone or with another drug (cadonilimab), in people with advanced solid tumors that cannot be removed by surgery. The goal is to see if the treatment can slow or stop cancer growth. About 63 participants will take part i…

This study tests a new tablet called ABP1011T in people with advanced solid tumors, including small cell lung cancer and others like esophageal or bladder cancer. Participants take one pill daily in 21-day cycles. The goal is to see if the drug can shrink tumors and how safe it i…

This early-phase study tests a new drug called ABX-001, given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the best dose. About 27 adults will t…

This study tests an oral drug called BAY 2927088 in people with advanced solid tumors that have HER2 gene mutations. About 111 adults will take the drug daily to see if it can shrink or control their cancer. The goal is to find a new treatment option for cancers like colorectal, …

This early-phase study tests a new drug called SYN818 combined with olaparib in adults with advanced solid tumors (including ovarian and breast cancers) that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 110 pa…

This early-stage study is testing a new drug, TGW101, in about 50 people with advanced solid tumors that have gotten worse after standard treatments. The main goals are to check if the drug is safe, what side effects it causes, and to find the best dose for future studies. Resear…

This early-stage study tests a new drug called SKB500 in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and side effects, and to see if it can shrink tumors. Researchers will also measure how the d…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This study tests a new drug called FL115 combined with an immunotherapy (PD-1 blocker) in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 130 adults w…

This early study is testing a new imaging agent called FL-261 in 12 people with advanced cancers like lung, colorectal, or head & neck cancer. The agent targets a protein called c-MET that is often found on cancer cells. Researchers want to see if FL-261 scans can safely and accu…

This study tests whether wearing a compression stocking on one foot during chemotherapy can prevent painful nerve damage caused by certain cancer drugs. About 58 adults with advanced cancers will wear a stocking on their left foot only, while the right foot serves as a comparison…

This study tests whether a simple card game called the Go Wish Game can help people with advanced blood cancers or solid tumors talk about what matters most to them at the end of life. About 75 patients will use the cards to identify their priorities and complete an advance care …

This study looks at how the antifungal drug itraconazole changes the levels of the cancer drug HS-20093 in the body. It involves 18 adults with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The goal is to measure drug concentrations over …

This early-phase study looks at how a new drug, rezatapopt, affects the way the body processes four common medicines (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to understand pote…